Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
07:00am, Monday, 06'th May 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference
09:02am, Tuesday, 02'nd Apr 2024
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Ch
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
07:00am, Tuesday, 02'nd Apr 2024
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pati
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
07:00am, Thursday, 07'th Mar 2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pati
Cara Therapeutics, Inc. (CARA) Q4 2023 Earnings Call Transcript
07:07pm, Monday, 04'th Mar 2024
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves -
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Monday, 04'th Mar 2024
Cara Therapeutics (CARA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.56 per share a year ago.
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Monday, 04'th Mar 2024
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)–
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
01:37pm, Sunday, 25'th Feb 2024
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
04:01pm, Monday, 12'th Feb 2024
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4
Cara Layoffs 2024: What to Know About the Latest CARA Job Cuts
10:19am, Monday, 22'nd Jan 2024
Cara Therapeutics (NASDAQ: CARA ) layoffs are coming for up to 50% of the biopharmaceutical company's employees as it shifts focus to its late-stage notalgia paresthetica program. Cara Therapeutics n
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
07:00am, Monday, 22'nd Jan 2024
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need –
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
01:32pm, Tuesday, 19'th Dec 2023
CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pru
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
07:32pm, Monday, 13'th Nov 2023
The headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript
07:20pm, Monday, 13'th Nov 2023
Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript November 13, 2023 4:30 PM ET Company Participants Matt Murphy - Manager of IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - Ch
